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Summary We have examined the efficacy, toxicity and host immunological response of two different dose
schedules of interleukin2 (IL-2) given subcutaneously, daily for 3 months in patients with renal cell carcinoma
(RCC) or metastatic melanoma (MM). We also examined the effect of adding the immune modulator
levamisole to the two different schedules of IL-2. Thirty-nine patients were entered into two sequential phase I/
II studies. Eighteen patients entered study 1 and were randomised to receive IL-2, 3 x 106 IU m- day-',
subcutaneously for 3 months with or without levamisole 50 mg t.d.s. p.o. on days 1-3 on alternate weeks.
Twenty-one patients entered study 2 and were randomised to receive 5.4x 106 IU m-2 day-1 subcutaneously
for 3months with or without levamisole 50 mg t.d.s. p.o. on days 1-3 on alternate weeks. Blood was taken for
peripheral blood lymphocyte (PBL) phenotype analysis, and measurement of IL-2, soluble IL-2 receptor (sIL-
2R) and neopterin concentration. Two patients with metastatic melanoma, one in each study, responded
(11.8%); both received IL-2 alone. Observations of immunological parameters showed that treatment with
subcutaneous IL-2 resulted in a significant rise in the percentage of PBLs bearing CD25, CD3/HLA-DR, CD56
and levels of IL-2 receptor and neopterin. The total white blood cell count (WBC) and total lymphocyte count
rose significantly on day 18 compared with pretreatment levels. The addition of levamisole to either IL-2
schedule resulted in no significant changes in any immunological parameters. This study illustrates that
prolonged subcutaneous IL-2 can be given safely in the outpatient setting. There was no evidence that
levamisole acts as an immunomodulator in this study.
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Interleukin 2 (IL-2) is an important immune modulator
expanding and activating T-cell subsets and natural killer
(NK) cells in vivo (Thompson et al., 1988; Hayat et al., 1991).
A number of strategies have been employed to try and
improve the efficacy of this modulation including the infusion
of lymphokine-activated cells (LAKs) derived from peripheral
blood lymphocytes which have been incubated in vitro with
IL-2 (Rosenberg et al., 1985). Other strategies have included
combination therapy with other cytokines such as interferon
and/or chemotherapy (Figlin et al., 1991; Richards et al.,
1992). IL-2 has single-agent activity in metastatic renal cell
carcinoma (RCC) and malignant melanoma (MM). Response
rates range between 10% and 24% in metastatic MM
(Whitehead et al., 1991; Rosenberg et al., 1989a) and
between 14% and 20% in metastatic RCC. (Rosenberg et
al., 1989b; Gore et al., 1994) and a small proportion of these
responses are durable (Rosenberg et al., 1989b, 1994).
IL-2 therapy is however associated with significant
toxicity. The objective and subjective toxicities of intrave-
nous IL-2 are well documented, often requiring hospitalisa-
tion and intensive medical management. Toxicities include
fever, bone marrow suppression, renal failure and vascular
leak syndrome.
There is an obvious need to develop less toxic and more
easily administered schedules, such as using the subcutaneous
route. Several studies in patients with metastatic RCC have
reported the use of subcutaneous IL-2 either on its own
(Atzpodien et al., 1990) or in combination with interferon
(Ratian et al., 1990; Kirchner et al., 1990) using a variety of
schedules. These studies have shown that IL-2 can be given
safely in the outpatient setting at doses of 0.3-
18 x 106 m-2 day-', with response rates of 22-36% (Ratian
et al., 1990; Atzpodien et al., 1990; Kirchner et al., 1990). The
toxicities experienced at the higher dose levels approached
those that are encountered when IL-2 is given intravenously.
Systemic toxicities of subcutaneously administered IL-2 at
lower dose levels are less severe and include transient
inflammation at injection sites, nausea, fever and chills
(Atzpodien et al., 1990; Ratian et al., 1990; Kirchner et al.,
1990; Steijfer et al., 1992). Recent reports have examined very
low-dose IL-2 administered as a continuous daily ambulatory
i.v. infusion for three months at a dose ranging between 0.5
and 6.0 x 106 IU m-2 day-' (Caligiure et al., 1991), and a
daily subcutaneous injection schedule at doses ranging
between 0.4 and 1.75 x 106 IU m-2 day-', also for 3 months
(Meropol et al., 1994). These studies have shown that low-
dose IL-2 can be given safely over a prolonged period of time
with minimal toxicity and results in significant expansion of
natural killer (NK) cells. Although such regimens have not
led to objective tumour regression, the immunological effects
that were seen warrant further investigation.
Levamisole has been widely used for many years as an
antihelminthic agent and immunomodulator and when given
on a fortnightly basis is without serious side-effects.
Laboratory and animal studies have suggested that
levamisole can restore the major functions of effector cells
where these are defective. It can also improve the decreased
cellular immunity that is encountered in a number of clinical
situations, e.g. ageing, post surgery and burns (Amery et al.,
1984). However, the data on the restoration of T-cell function
in patients with cancer is conflicting (Obiri et al., 1989;
Tempero et al., 1990).
In this paper we examine the efficacy, toxicity and
immunological responses of two different dose schedules of
IL-2 given subcutaneously over a prolonged period (3
months) in an outpatient setting. In addition, patients were
randomised to receive levamisole with IL-2 or IL-2 alone in
order to examine the role of levamisole as an immunomo-
dulator in the context of IL-2.
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Materials and methods
Patients
Patients with histologically proven MM or RCC who had
evidence of disseminated or uncontrolled local disease were
eligible for the two studies which ran consecutively over a 21
month period. Patients with measurable progressive disease
assessable by physical examination or non-invasive radiolo-
gical procedures were eligible for both studies. Eligibility
criteria included performance status 0-2 (ECOG); age 18
years or over; life expectancy greater than 3 months;
adequate haematological parameters (WBC>3.0 x 1O' 1-1,
platelets> 100 x 109 1-1, Hb> 10 g 1-1); liver function tests
not elevated more than twice the normal range; normal serum
creatinine, or an EDTA clearance>65 ml min-'; and normal
urea and electrolytes. Patients were excluded if they were
pregnant, lactating or had any serious underlying medical
conditions or a psychiatric impairment limiting consent.
Patients with a previous history of cancer, concurrent second
malignancy or cerebral metastases were excluded. Patients
could not receive steroids or cimetidine for 2 weeks before
study entry or while receiving IL-2. The protocol was
approved by the Royal Marsden Hospital Ethics Committee
and all patients gave written informed consent.
Treatment
Patients were admitted for initial assessment and instruction
by nursing staff on the self-administration of IL-2 via the
subcutaneous route. Patients were randomised in study 1 to
receive IL-2 3 x 106 IU subcutaneously (s.c.) daily for 90 days
with or without levamisole, 50 mg t.d.s. orally on days 1-3
on alternate weeks. Patients randomised in study 2 received
IL-2 5.4 x 106 IU s.c. daily for 3 months with or without
levamisole 50 mg t.d.s. orally on days 1-3 on alternate
weeks. Treatment was delivered on an outpatient basis.
Response and toxicity assessment
Before study entry, patients had blood taken for the
following tests: full blood count, creatinine, liver function
tests, calcium, clotting screen, thyroid function tests and
thyroid autoantibodies. These were repeated at 3, 7, 11 and
12 weeks and monthly thereafter if treatment continued
beyond 12 weeks. Chest radiograph and other radiological
investigations appropriate to disease site e.g. computerised
axial tomography (CT scan) or ultrasonography (US) were
performed before treatment and repeated at monthly
intervals. Patients were assessed for response at monthly
intervals using appropriate imaging (CT, X-ray, US).
Treatment was stopped in any patient who developed
progressive disease. Patients who achieved a partial remis-
sion (PR) following completion of the study received a
further 1 month of treatment. Subjective toxicities were
assessed monthly and graded using the WHO criteria (WHO,
1979).
Response was defined according to World Health
Organization (WHO) criteria (WHO, 1979) as follows: a
complete response (CR) as disappearance of all known
disease determined by two observations not less than 4
weeks apart; a partial response (PR) as a >50% decrease in
the product ofbidimensionally measurable lesions determined
by two observations not less than 4 weeks apart with no new
lesions appearing; stable disease (SD) as a <50% decrease
and <25% increase in the size ofbidimensionally measurable
lesions; progressive disease (PD) as a >25% increase in the
size of measurable lesions and/or the appearance of new
lesions.
Assessment of immunological parameters
Blood samples from the patients were obtained by
venepuncture and collected into sterile vacutainers (Becton
Dickinson, Oxford, UK) containing either no anticoagulant
(for serum), lithium heparin (for plasma), or EDTA (for full
blood counts and flow cytometry). All patients were bled
pretreatment (day 0) and on treatment days 4, 15, 18 and 46
depending on whether treatment was completed or whether
the patients stopped treatment owing to disease progression.
Flow cytometry Monoclonal antibodies (Coulter Electronics,
Beds) against the following lymphocyte surface markers were
used: CD2 (pan T cell, reference range 1215-2532
counts PI 1); CD3 (pan T cell, reference range 929-2471
counts PI`1); CD8 (cytotoxic/suppressor T cell, reference
range 243-1013 counts PI`h); CD19 (pan-B cell, reference
range 89-691 counts I-1); CD25 (interleukin 2 receptor p55
(IL-2R), reference range 18- 180 counts Pul 1); CD56 (natural
killer cell, NK, reference range 28-682 counts PI`1); and
CD3/HLA-DR-positive cells (activated T cells, reference
range 5-112 counts dl-'). Laboratory reference ranges were
derived from a maximum of 28 normal laboratory volunteers
(age range 21-50 years) and are expressed as two standard
deviations (s.d.) from the mean. Monoclonal antibody (10 pl)
was added to 100 ,ul of whole blood (EDTA) and vortexed.
After 10 min at room temperature the red blood cells were
lysed and the sample buffered and fixed using the Counter Q-
Prep system. The cell surface markers were then analysed on
a Coulter Epics Profile II flow cytometer. A model T-540
haematology analyser (Coulter) was used to assess total white
blood cell and lymphocyte counts for which the manufac-
turer's reference ranges were 4.8-10.8 x109 1'- and 1.2-
3.4 x I09 1- respectively.
Serumfactors Serum IL-2 was detected using an ELISA kit
(British Biotechnology Limited, Oxford) according to the
manufacturer's instructions. The upper limit of normal was
31.3 pg ml-'. Soluble IL-2 receptor was detected using an
ELISA kit (T Cell Sciences, Laboratory Impex, Middlesex).
The upper limit of normal was 919 U ml-'. Neopterin was
measured by a commercially produced radioimmunoassay
(Henning Berlin, Tyne and Wear). The upper limit of the
reference range for adults is 10 nmol 1-'.
Statistical analysis
The means of all immunological parameters and serum
factors were calculated pretreatment and on the specified
treatment days (see sample collection). These values were
then plotted against time for each study group. Analyses
examining the changes from pretreatment levels were
performed. The significance of changes from prestudy levels
to day 18 and day 46 were assessed by testing whether the
change in scores were significantly non-zero using the
Wilcoxon test. In order to determine whether changes
differed between the two randomised groups with and
without levamisole or to see whether there was evidence of
a different effect between the two studies, the Mann-
Whitney test was used to compare the changes in the two
studies being assessed at day 18. However, the comparison
between studies was non-randomised and was therefore
confounded by the difference between the study groups. A
large number of significance tests was undertaken, hence it
would be expected that a large number of spuriously
significant results would be obtained. A multiple comparison
correction was therefore applied and results were only
emphasised if they satisfied P<0.002.
Results
Response
A total of 18 patients were randomised in study 1, but only
17 patients were evaluable for response as one patient died of
a myocardial infarction shortly after randomisation and
before treatment began. Of these 17 patients, five had RCC
and 12 had MM. Eight patients received IL-2 alone and nine
patients received IL-2 with levamisole. One patient had a PRIL-2 with/without levamisole in RCC and melanoma
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and two patients had SD. There were no CRs and the other
14 patients had PD. Twenty-one patients were randomised in
study 2: five had MM and 16 had RCC. Ten patients received
IL-2 alone and 11 patients received IL-2 with levamisole. One
patient had a PR, eight patients had SD and 12 patients had
PD. Overall, in studies 1 and 2, 2 out of 17 patients with MM
had a PR (11.8%) and ten patients had SD, all of whom also
had MM. No patients with RCC responded or had
stabilisation of their disease. The two responding (MM)
patients received IL-2 alone.
Toxicity
All patients in both study 1 and 2 were evaluable for toxicity.
No grade 4 toxicity was seen in either study. Table I shows
all grade 2-3 toxicities for both studies 1 and 2. Fatigue was
infrequent when IL-2 was given alone at the low-dose
schedule, but when levamisole was added the incidence of
fatigue increased to that seen in both arms of the higher dose
study. Only patients in study 2 experienced grade >2
cutaneous toxicity. One patient experienced moderate
depression in study 2 but this did not require treatment.
There were no episodes of hypotension or systemic infection
in either study.
Immunological responses
There was no evidence that any individual immunological
parameters changed significantly with the addition of
levamisole in either study. The total white blood cell count
remained stable in all groups over the first 4 days of
treatment. The absolute number, and hence proportion, of
lymphocytes decreased in the first 4 days (27.9% pretreat-
ment- 19.5% on day 4). Thereafter, the white blood cell
Table I Number of patients with grade 2 and 3 toxicity/total
number of patients
Study I Study 2
IL-2 and IL-2 and
IL-2 alone levamisole IL-2 alone levamisole
Nausea and 4/8 5/9 4/10 2/11
vomiting
Fever 1/8 3/9 5/10 5/11
Cutaneous 0/8 0/9 6/10 5/11
Fatigue 2/8 7/9 9/10 8/11
Chills 0/8 0/9 1/10 2/11
Anorexia/ 0/8 4/9 4/10 3/11
weight loss
There were no grade 4 toxicities and no systemic infections observed.
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Figure 1 Changes in total white blood count in studies 1 and 2.
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count rose progressively with peak values occurring on days
15 or 18 (Figure 1). The lymphocyte count rose proportion-
ately (Figure 2). After day 18 there was a progressive
decrease in both these counts (Figures 1 and 2).
Changes in peripheral blood lymphocytes bearing the
CD2, CD3 and CD8 phenotypic markers were all in
proportion to those seen for the total white blood cell
count: CD3 mean 71% (range 57.1-80.1); CD2 mean 85.5%
(range 66.6-92.6); CD8 mean 23.8% (range 13.0-31.2).
Cumulative data from both studies showed that the
administration of IL-2 resulted in a significant rise in the
percentage of peripheral blood lymphocytes bearing CD25,
CD3/HLA-DR, CD56 and levels of soluble IL-2 receptor,
neopterin, WBC and absolute lymphocyte count on day 18
compared with pretreatment values (P<0.001, Tables II and
III). Over the entire treatment period the proportion of
peripheral blood lymphocytes bearing CD25 and CD56 was
maintained on days 46 in both studies (comparisons of
pretreatment values and those achieved on day 46 were not
possible due to too few observations being made).
Soluble IL-1 receptor levels increased over the study
period, higher levels being achieved in study 2 at the higher
dose level of subcutaneous IL-2. There was a suggestion that
the total lymphocyte count was also more elevated in study 2
compared with study 1, but this did not reach statistical
significance (P=0.015). The dose-dependent response for IL-
2 receptor and total lymphocyte count needs to be interpreted
with caution as the dosing of IL-2 was not randomised.
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Figure 2 Changes in absolute lymphocyte count in studies 1 and
2.
Table II Analysis of changes in total white blood count (WBC),
absolute lymphocyte count and peripheral blood lymphocyte
phenotypes between prestudy levels and days 18 and day 46 for
both studies
Pretreatment Day 18 Day 46
Mean Mean Mean
(95% CI (95% CI (95% CI
for mean) for mean) for mean)
CD56% 11.7 24.9** 30.8**
(counts pl-1) (8.8-14.6) (20.3-29.5) (22.3-39.3)
CD25% 4.9 11.0** 11.4**
(counts jul-) (4.0-5.7) (8.9-13.0) (9.2-13.6)
CD3/HLA-DR% 4.2 8.5** 5.7*
(counts idr1) (3.2-5.3) (5.7-11.3) (4.1-7.2)
WBC 8.0 14.6** 11.5*
(x1091-l) (7.0-9.0) (12.9-16.4) (9.6-13.5)
Lymphocyte count 2.2 4.5** 3.7*
(X 109 1-1) (1.9-2.5) (3.7-5.3) (3.0-4.3)
*P<0.05, **P<0.001.
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Table III Analysis of changes in serum parameters between
prestudy levels and days 18 and day 46 for both studies (cumulative
data)
Pretreatment Day 18 Day 46
Mean Mean Mean
(95% CI (95% CI (95% CI
for mean) for mean) for mean)
Soluble IL-2 receptor 4859 13843** 10682*
(U mlr) (3337-6381) (9358-18329) (6380-14974)
Neopterin 12.6 28.3** 26.4
(nmol 1-1) (8.7-16.5) (18.2-38.4) (11.4-41.3)
Serum IL-2 0 38.5 57
(pg ml-') (0-101) (9.6-65) (11.5-29.8)
*P<0.05, **P<0.001.
Discussion
It is assumed by many groups that intermittent boosting
doses of IL-2 are required to maintain sufficient activation of
the immune response. Our study set out to examine the
alternative, namely that chronic administration of IL-2 at a
constant dose can also result in significant stimulation of the
immune system. In addition, we explored the possibility of
further modulating the immune response with levamisole. We
have shown that the pattern of lymphocytosis is similar when
IL-2 is given subcutaneously compared with parenterally
(Dadian et al., 1993) and that increases in peripheral blood
lymphocyte activation markers (CD25, CD3/HLA-DR) occur
at low doses of IL-2, such as those used in study 1. We have
also shown that, at low doses of IL-2, soluble IL-2 receptor
levels in the serum are increased, an observation that is well
documented with other IL-2 schedules (Lissoni et al., 1991).
Furthermore, there is a suggestion from our study that this
induction of soluble IL-2 receptor is dose dependent (data
not shown). Our study shows that, after a prolonged period
of treatment (day 46), immunological parameters were
increased compared with pretreatment levels, but as IL-2
administration continued there was a trend for them to
decrease with time and levamisole did not appear to reverse
this. For instance, levamisole failed to affect the plateauing of
absolute lymphocyte numbers or the percentage of activated
lymphocytes (CD25-positive cells). It remains to be
determined whether this slight decrease in immune activation
would become more marked with time, e.g. after 6 months of
treatment, and hence clinically relevant.
We saw an increase in fatigue among patients receiving
levamisole in study 1. This increase could be accounted for
by an increased induction of interferon gamma (IFN-y ) as
it is well established that fatigue is one of the side-effects of
this cytokine and it is known that IL-2 induces it.
Interestingly, patients receiving low-dose IL-2 with levami-
sole in our study had the same incidence of fatigue as those
patients receiving twice the dose of IL-2. However, we did
not find any difference in the levels of neopterin measured at
either dose schedule of IL-2, nor did we find that levamisole
altered its serum concentration. Neopterin is considered to
be a sensitive marker of interferon gamma induction and
therefore the apparent increase in fatigue seen at low doses
of IL-2 with levamisole may be due to a different
mechanism.
We found no evidence that the addition of levamisole
results in any significant changes in immunological para-
meters with either low- or high-dose subcutaneous IL-2.
Thus, the role of levamisole as a modulator of IL-2-induced
responses has not been confirmed. We have, however, shown
that subcutaneous IL-2 can be given daily without a break in
the outpatient setting and with minimal toxicity. We have
also demonstrated that immune activation is seen at these low
non-toxic doses with a plateauing of the immune response
between days 18 and 46, suggesting that this activation is
maintained. The role of continuously delivered subcutaneous
IL-2 needs to be examined further because, although we have
demonstrated objective tumour reponses in this study, many
questions remain unanswered, such as the optimal subcuta-
neous dose of IL-2, the frequency of administration and the
necessity for intermittent boosting.
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